logo
Twitter
Discord
Email
logo
MediWound Ltd.

MediWound Ltd.

NASDAQ•MDWD
CEO: Mr. Ofer Gonen B.Sc.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2014-03-20
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Contact Information
42 Hayarkon Street, Yavne, 8122745, Israel
972-7-797-14100
www.mediwound.com
Market Cap
$192.27M
P/E (TTM)
-9.5
37
Dividend Yield
--
52W High
$22.51
52W Low
$14.14
52W Range
43%
Rank51Top 71.3%
3.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$5.43M+24.66%
4-Quarter Trend

EPS

-$0.24-75.51%
4-Quarter Trend

FCF

-$3.70M-25.16%
4-Quarter Trend

2024 Annual Earnings Highlights

Key Highlights

Total Revenues Increased Total revenues reached $20.22M USD in 2024, up 8% from $18.69M USD, driven by Vericel sales and new DoD contracts.
Manufacturing Capacity Expansion New GMP facility construction completed August 2024; expected to reach sixfold output capacity by the end of 2025, pending regulatory approvals.
NexoBrid Pediatric Approval FDA expanded NexoBrid approval in August 2024 to include pediatric patients (newborn through 18 years old) for thermal burns treatment.
EscharEx Phase III Initiated Initiated global pivotal Phase III VALUE trial for EscharEx in February 2025, targeting venous leg ulcers treatment across 40 sites.

Risk Factors

Sustained Net Loss History Incurred net loss of $30.22M USD for 2024, continuing history of losses; accumulated deficit reached $205.0M USD as of year-end.
Sole Bromelain Supplier Risk Reliance on single supplier, CBC in Taiwan, for bromelain SP exposes supply chain to geopolitical tensions or operational failures.
Regulatory Approval Uncertainty Development of EscharEx and pipeline candidates requires successful regulatory approval processes which may suffer significant delays or outright failure.
Israel Geopolitical Instability Ongoing hostilities in Israel, including missile attacks, may materially affect operations, workforce availability, and regional economic conditions.

Outlook

Scaling Manufacturing Operations Facility expected to reach full operational capacity by end of 2025, increasing manufacturing output sixfold to meet growing global demand.
Advancing EscharEx Pipeline Planning adaptive Phase II/III trial for diabetic foot ulcers (DFUs) starting in 2026, alongside ongoing VLU trials.
Liquidity Position Assessment Existing cash and deposits of $43.6M USD expected to fund operations and capital expenditure for at least twelve months from report date.

Peer Comparison

Revenue (TTM)

Genfit S.A.GNFT
$126.71M
+9.8%
Codexis, Inc.CDXS
$52.93M
-17.9%
Assembly Biosciences, Inc.ASMB
$37.19M
+31.3%

Gross Margin (Latest Quarter)

Genfit S.A.GNFT
100.0%
+0.0pp
Assembly Biosciences, Inc.ASMB
100.0%
+0.0pp
Sangamo Therapeutics, Inc.SGMO
100.0%
+4.3pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
SLS$449.02M-17.8-95.2%1.2%
GNFT$309.74M-7.1-63.7%64.1%
EPRX$301.32M-11.8-62.6%0.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-2.4%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 18, 2026
|
EPS:-$0.59
|
Revenue:-
Reports
All Years

  • Form 20-F - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 19, 2025|
    Revenue: $20.22M+8.2%
    |
    EPS: $-3.03-304.0%
    Miss

  • Form 20-F - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 21, 2024|
    Revenue: $18.69M-29.5%
    |
    EPS: $-0.75+80.9%
    Miss

  • Form 20-F - FY 2022

    Period End: Dec 31, 2022|Filed: Mar 16, 2023|
    Revenue: $26.50M+11.5%
    |
    EPS: $-3.93-12.9%
    Miss

  • Form 20-F - FY 2021

    Period End: Dec 31, 2021|Filed: Mar 17, 2022|
    Revenue: $23.76M+9.2%
    |
    EPS: $-3.48-46.2%
    Beat

  • Form 20-F - FY 2020

    Period End: Dec 31, 2020|Filed: Feb 25, 2021|
    Revenue: $21.76M-31.5%
    |
    EPS: $-2.38-288.9%
    Beat